32.9 C
Karachi
Thursday, March 28, 2024
- Advertisement -
 

Russia completes early trials of second COVID-19 vaccine

TOP NEWS

Reuters
Reuters
Reuters is an international news organisation owned by Thomson Reuters

MOSCOW: Siberia’s Vector virology institute on Tuesday completed early-stage human trials, known as Phase II, of a second potential Russian vaccine against COVID-19, the state consumer safety watchdog was cited by the Interfax news agency as saying.

Russia registered its first vaccine candidate, developed by Moscow’s Gamaleya Institute, in August. Late-stage trials of this vaccine, due to involve 40,000 participants, were launched last week.

Human trials of the second potential COVID-19 vaccine, a peptide-based jab, began on July 27 and involved a group of 100 volunteers, Interfax cited watchdog Rospotrebnadzor as saying.

“Today … the final group of 20 volunteers was released from hospital,” said in a statement. “All 100 volunteers were vaccinated with two doses and have completed a 23-day monitoring period in hospital. The volunteers are feeling good.”

Results are due to be published on Sept. 30, Interfax said.

- Advertisement -
- Advertisement -
 

POLL

Will the PML-N led govt be able to steer Pakistan out of economic crisis?

- Advertisement -
 

MORE STORIES